KIR3DL2 (CD158k) is a potential therapeutic target in primary cutaneous anaplastic large-cell lymphoma.

Date publication

août 2016

Journal

The British journal of dermatology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BENSUSSAN Armand

Tous les auteurs :
Battistella M, Janin A, Jean-Louis F, Collomb C, Leboeuf C, Sicard H, Bonnafous C, Dujardin A, Ram-Wolff C, Kadin ME, Bensussan A, Bagot M, Michel L

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/27037558

Résumé

KIR3DL2, an inhibitory receptor expressed by natural killer cells and a subset of normal CD8(+) T cells, is aberrantly expressed in neoplastic cells in transformed mycosis fungoides and Sézary syndrome. Anti-KIR3DL2 targeted antibody therapy has shown potent activity in preclinical models for these diseases.

Mots clés

Adolescent, Adult, Aged, Antibodies, Monoclonal, pharmacology, Antineoplastic Agents, pharmacology, Cell Line, Tumor, Female, Humans, Ki-1 Antigen, metabolism, Killer Cells, Natural, physiology, Leukocytes, Mononuclear, metabolism, Lymphoma, Large-Cell, Anaplastic, drug therapy, Male, Middle Aged, Receptors, KIR2DL2, antagonists & inhibitors, Skin, metabolism, Skin Neoplasms, drug therapy, Tumor Cells, Cultured, Young Adult

Référence

Br J Dermatol. 2016 08;175(2):325-33